Near Patient Diagnostics for Women’s Health
Delivering peace of mind through accurate testing
Our Platform = Our Assay + Our Instrument + Proximity
We’ve taken a bulky, costly, slow, and narrowly focused process and streamlined it down into an integrated, multi-analyte, algorithmic platform that is positioned closer to the patient, enabling faster, more accurate and less costly testing.
Our platform allows you to processes samples in less than 30 minutes, compared to 2+ hours for ELISA.
Our platform (assay and instrument) has been designed for accuracy, with results of ~98% sensitivity*, ~98% specificity*.
Multiplex up to 32 analytes in a single run, resulting in efficiencies and reduced operating costs as low as $5 a sample.
Easy on Patients
Our testing protocol requires only 100 µL samples, reducing the impact on the patients.
Our platform can test for Bacteria, Viruses, and Proteins.
Our solution is positioned near patients; results are delivered to healthcare providers more rapidly than conventional methods.
* Coronavirus Antigen
Demo of MultiomeDX Readers
Demo of MultiomeDx Assay
The Power of the MultiomeDx Platform
Using 100 µL of blood serum, plasma, or saliva, our platform has been built to minimize impact to patients and for accuracy, speed, and efficiency.
Our Platform Empowers Patients
- It saves patients time
- It saves the patient’s money
- Offers less invasive testing
- Allows the patient to screen for risk factors*
* Requires our mobile app.
|Modified sandwich immunoassay on filter membrane of VF Cartridge
|UV LED excitation to scan 34 well VF cartridge array
|Dynamic Range Sensitivity
(for protein detection)
|4 logs 20 pg/mL
|Fluorescence measurement on VF Cartridge using proprietary read head and reading algorithm
* Coronavirus Antigen
Our team brings a wealth of experience and expertise to bear on the problem.
Co-Founder Su Dwarakanath has worked in the industry for over 30 years. While at various diagnostics companies, she realized that there is a definite need for Point-of-Care testing that can combine the accuracy of a large diagnostic platform and the speed of POC.
Realizing that the holes in the market could be solved with technology, she combined her assay development skills with her co-founder’s, Sri Satyanarayana, engineering skills to create the MutliomeDx’s AutoVega platform for the development of immune assay with high accuracy and speed.
Su Dwarakanath, PhD
Founder & CEO
Roche,Thermo Fisher Scientific, Bayer Diagnostics, Nano Science Diagnostics
New York University
Sri Satyanarayana, PhD
Founder & CTO
IBM, AT&T Bell Labs, Hughes Research Labs, Philips, Free Electron Technology, Nano Science Diagnostics, Full power Technologies
Finance professional with over 20 years of corporate finance, structuring, and management.
New York Law School
Dr. Dev Shukla, Executive Chairman
Rajan Pillai Esq., Advisor
Dr. Sulatha Dwarakanath, CEO & Co-founder
Dr. Srinagesh Satyanarayana, CTO, Co-founder (Observer)
Scientific Advisory Board
Alex Melamed, MD, Gynecologic Oncologist Massachusetts General Hospital/Harvard Medical School
George Caughey MD, Immunologist Critical care UCSF
Alley Tevrizian, MD, Immunologist
Nancy Mozelsio, MD, Immunologist
Mitch Levinson, Serial Entrepreneur
Shailja Dixit, MD, MBA, CEO/founder Curio